ETS1 and urinary bladder cancer: Specifically, MLL mutation in recurrent bladder cancer samples and T24 cell lines acquired the elevated H3K4me3 activity and transcriptional activation of target genes GATA4 and ETS1. The increased expression of GATA4 and ETS1 contributed to enhance the drug-resistance ability during the progression and recurrence of bladder cancer.